Citations

Showing 10 of 108152 citations.

The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome
Mohr, Sandra , Fritz, Nikola, Hammer, Christian , Martínez, Cristina , Berens, Sabrina , Schmitteckert, Stefanie , Wahl, Verena, Schmidt, Målin , Houghton, Lesley A. , Goebel‐Stengel, Miriam , Kabisch, Maria, Götze, Dorothea, Milovač, Irina , D’Amato, Mauro , Röth, Ralph , Mönnikes, Hubert, Engel, Felicitas , Gauss, Annika , Tesarz, Jonas , Raithel, Martin , Andresen, Viola , Frieling, Thomas , Pehl, Christian, Stein‐Thöringer, Christoph, Clarke, Gerard , Kennedy, Paul J. , Cryan, John F. , Spiller, Robert E. , Beltrán, Caroll J. , Madrid, Ana María , Torres, Verónica , Arce, Edith Pérez de , Herzog, Wolfgang , Sayuk, Gregory S. , Karamanolis, George, Pojskić, Lejla , Bustamante, Mariona , Rabionet, Raquel , Estivil, Xavier, Wouters, Mira M. , Rappold, Gudrun , Santos, Javier , Schaefert, Rainer , Niesler, Beate , Zheng, Tenghao , Engel, Felicitas , Gauss, Annika , Tesarz, Jonas , Raithel, Martin , Andresen, Viola , Frieling, Thomas , Keller, Jutta , Stein-Thöringer, Christoph , Clarke, Gerard , Kennedy, Paul J , Cryan, John F , Dinan, Timothy G , Quigley, Eamonn M M , Spiller, Robin , Madrid, Ana María , Pérez de Arce, Edith , Herzog, Wolfgang , Mayer, Emeran A , Sayuk, Gregory , Gazouli, Maria , Karamanolis, George , Kapur-Pojskič, Lejla , Bustamante, Mariona , Rabionet, Raquel , Estivil, Xavier , Franke, André , Lieb, Wolfgang , Boeckxstaens, Guy , Wouters, Mira M , Simrén, Magnus , Rappold, Gudrun A , Vicario, Maria , Santos, Javier , Schaefert, Rainer , Lorenzo-Bermejo, Justo , Niesler, Beate , D'Amato, Mauro , Houghton, L A , Martínez, Cristina , Zheng, Tenghao , Stein-Thöringer, Christoph K., Quigley, Eamonn M.M. , Torres, Verónica, Boeckxstaens, Guy E. , Simrén, Magnus , Bermejo, Justo Lorenzo

Mayo Clinic

Journal of Cellular and Molecular Medicine | June 24, 2021 | Volume: 25 | Issue: 16 | Pages: 8047-8061

10.1111/jcmm.16736 | PMID 34165249 Get It

AbstractIrritable bowel syndrome (IBS) is a gut‐brain disorder in which symptoms are shaped by serotonin acting centrally and peripherally. The serotonin transporter gene SLC6A4 has been implicated in IBS pathophysiology, but the underlying genetic mechanisms remain unclear. We sequenced the alternative P2 promoter driving intestinal SLC6A4 expression and identified single nucleotide polymorphisms (SNPs) that were associated with IBS in a discovery sample. Identified SNPs built different haplotypes, and the tagging SNP rs2020938 seems to associate with constipation‐predominant IBS (IBS‐C) in females. rs2020938 validation was performed in 1978 additional IBS patients and 6,038 controls from eight countries. Meta‐analysis on data from 2,175 IBS patients and 6,128 controls confirmed the association with female IBS‐C. Expression analyses revealed that the P2 promoter drives SLC6A4 expression primarily in the small intestine. Gene reporter assays showed a functional impact of SNPs in the P2 region. In silico analysis of the polymorphic promoter indicated differential expression regulation. Further follow‐up revealed that the major allele of the tagging SNP rs2020938 correlates with differential SLC6A4 expression in the jejunum and with stool consistency, indicating functional relevance. Our data consolidate rs2020938 as a functional SNP associated with IBS‐C risk in females, underlining the relevance of SLC6A4 in IBS pathogenesis.
Updates in the management of relapsed/refractory multiple myeloma
Hanna, Kirollos S. , Larson, Samantha, Tu, Sarah, Boudreau, Jenna, Rose, Sarah, Nguyen, Jenny , Rose, Sarah

Mayo Clinic

Journal of Oncology Pharmacy Practice | June 24, 2021 | Volume: 27 | Issue: 6 | Pages: 1477-1490

10.1177/10781552211028906 | PMID 34162244 Get It

Multiple myeloma, a malignant neoplasm of plasma cells that accumulate in bone marrow, accounts for approximately 18% of hematologic malignancies in the United States. Patients are often treated with triplet therapy and may undergo stem cell transplantation. Despite effective therapies, multiple myeloma remains incurable. Patients often require maintenance therapy, and many will progress or relapsed following upfront treatment. Selection of treatment in the relapse/refractory setting is complex due numerous active therapeutic agents and combinations. Treatment is often tailored to prior exposure and duration. In 2020, three novel pharmacological agents were approved in the relapsed setting. We highlight the clinical safety and efficacy of selinexor, isatuximab-irfc, and belantamab mafodotin for patients with multiple myeloma.
Novel targets for refractory kidney cancer: Where are we heading?
Sarkis, Julien , Sarkis, Pierre, Alkassis, Marwan , Ghazi, Rabih , Assaf, Joy

Mayo Clinic

Journal of Oncology Pharmacy Practice | June 24, 2021 | Volume: 27 | Issue: 6 | Pages: 1559-1561

10.1177/10781552211027216 | PMID 34162246 Get It

The Top 50 Most‐Cited Knee Arthroscopy Studies
Murphy, Sierra , McQuivey, Kade S. , Murphy, Sierra N, Bingham, Joshua S. , Moore, M. Lane , Pollock, Jordan Riley

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | June 24, 2021 | Volume: 3 | Issue: 4 | Pages: No page available

10.1016/j.asmr.2021.05.006 | PMID 34430905 Get It

Purpose To objectively identify the 50 most influential studies in knee arthroscopy and provide an analysis of their key characteristics. Methods The Clarivate Analytics Web of Knowledge database was used to gather data and metrics of knee arthroscopy research. The search list was sorted by the number of citations, and articles were included or excluded based on relevance to knee arthroscopy. The information extracted for each article included author name, publication year, country of origin, journal name, article type, and the level of evidence. Results For these 50 studies, the total number of citations was calculated to be 12,168, with an average of 243.4 citations per paper. The most‐cited article was cited 1,220 times. The 50 studies included in this analysis were published between 1972 and 2013. All 50 articles were published in English and came from 10 different orthopaedic journals. The United States was responsible for the majority of articles (n = 26); however, many other countries were represented. The most prevalent study designs were case series (n = 20). Conclusions The 50 most influential articles in knee arthroscopy were cited a total of 12,168 times. The study designs most commonly used were case series and cohort studies. This article serves as a reference to direct orthopaedic practitioners to the 50 most influential studies in knee arthroscopy. We hope that these 50 studies and the analysis we provide help health care professionals efficiently assess consensus, trends, and needs within the field. Clinical Relevance This analysis of the 50 most influential studies in knee arthroscopy will provide medical students, residents, fellows, and attending physicians with a comprehensive inventory and citation analysis of the most impactful academic contributions to one of the most important fields within orthopaedic surgery.
Industry Payments to Practicing US Rheumatologists, 2014–2019
Putman, Michael , Goldsher, Jay E., Crowson, Cynthia S. , Duarte‐García, Alí , Putman, Michael S , Duarte-García, Alí

Mayo Clinic

Arthritis & Rheumatology | June 24, 2021 | Volume: 73 | Issue: 11 | Pages: 2138-2144

10.1002/art.41896 | PMID 34164951 Get It

ObjectivePayments from the pharmaceutical industry to practicing physicians may influence prescribing behavior. This study was undertaken to investigate the nature, quantity, and geographic distribution of payments to US rheumatologists.MethodsGeneral payments from industry sponsors to US rheumatologists from 2014 to 2019 were extracted from the Centers for Medicare and Medicaid Services Open Payments database. Gender was identified by linking physicians to the National Plan and Provider Enumeration System registry. Data were reported in aggregate, trends over time were assessed using linear regression models, and differences by gender were analyzed using the Wilcoxon rank sum test.ResultsOver the 6‐year time period from 2014 to 2019, a total of 1,610,668 payments totaling $221,254,966 were made to 5,723 rheumatologists. The median payment was $15 (interquartile range [IQR] $10 to $22), and the median total amount received by individual rheumatologists over the 6‐year period was $2,818 (IQR $464 to $11,560). The majority of rheumatologists (3,416 of 5,723 [60%]) received less than $5,000, but 368 of 5,723 (6%) received more than $100,000 each and accounted for 78% of the total. The yearly value of payments increased over time ($3,703,264 per year; P < 0.001), and the median payment to male rheumatologists was significantly higher than the median payment to female rheumatologists ($3,723 [IQR $542 to $15,841] versus $2,084 [IQR $394 to $8,186]; P < 0.001).ConclusionThe value of industry payments has increased over time, and a large amount is concentrated among a small number of rheumatologists. Future studies should investigate the degree to which industry payments have influenced prescribing in the field of rheumatology.
Profound Hypotonia and Respiratory Failure due to Suspected Nemaline Myopathy in a Preterm Infant
Akuamoah-Boateng, Gloria, Stetson, Raymond C. , Kaemingk, Bethany D. , Bieber, David A., Brumbaugh, Jane E.

Mayo Clinic

American Journal of Perinatology Reports | June 23, 2021 | Volume: 11 | Issue: 02 | Pages: e91-e94

10.1055/s-0041-1728782 | PMID 34178423 Get It

AbstractCongenital myopathies, such as nemaline myopathy, may present with hypotonia and respiratory failure in the neonatal period. Respiratory function can be further compromised in affected infants by the development of chylous effusions. We present the case of a preterm male infant born at 326/7 weeks' gestation, who was profoundly hypotonic and required intubation at birth. His clinical course progressed from acute to chronic respiratory failure with mechanical ventilation dependence. He developed bilateral chylous pleural effusions during the newborn period. Whole exome sequencing identified an ACTA1 gene mutation leading to the presumed diagnosis of nemaline myopathy. This case highlights the need to include congenital myopathies in the differential for a preterm newborn with hypotonia and respiratory failure.
Optimizing Clinical Monitoring Tools to Enhance Patient Review by Pharmacists
Schreier, Diana J., Lovely, Jenna K.

Mayo Clinic

Applied Clinical Informatics | June 23, 2021 | Volume: 12 | Issue: 03 | Pages: 621-628

10.1055/s-0041-1731341 | PMID 34161988 Get It

AbstractBackground The Clinical Monitoring List (CML) is a real-time scoring system and intervention tool used by Mayo Clinic pharmacists caring for hospitalized patients.Objective The study aimed to describe the iterative development and implementation of pharmacist clinical monitoring tools within the electronic health record at a multicampus health system enterprise.Methods Between October 2018 and January 2019, pharmacists across the enterprise were surveyed to determine opportunities and gaps in CML functionality. Responses were received from 39% (n = 162) of actively staffing inpatient pharmacists. Survey responses identified three main gaps in CML functionality: (1) the desire for automated checklists of tasks, (2) additional rule logic closely aligning with clinical practice guidelines, and (3) the ability to dismiss and defer rules. The failure mode and effect analysis were used to assess risk areas within the CML. To address identified gaps, two A/B testing pilots were undertaken. The first pilot analyzed the effect of updated CML rule logic on pharmacist satisfaction in the domains of automated checklists and guideline alignment. The second pilot assessed the utility of a Clinical Monitoring Navigator (CMN) functioning in conjunction with the CML to display rules with selections to dismiss or defer rules until a user-specified date. The CMN is a workspace to guide clinical end user workflows; permitting the review and actions to be completed within one screen using EHR functionality.Results A total of 27 pharmacists across a broad range of practice specialties were selected for two separate two-week pilot tests. Upon pilot completion, participants were surveyed to assess the effect of updates on performance gaps.Conclusion Findings from the enterprise-wide survey and A/B pilot tests were used to inform final build decisions and planned enterprise-wide updated CML and CMN launch. This project serves as an example of the utility of end-user feedback and pilot testing to inform project decisions, optimize usability, and streamline build activities.
Blinded review of hippocampal neuropathology in sudden unexplained death in childhood reveals inconsistent observations and similarities to explained paediatric deaths
Leitner, Dominique , McGuone, Declan , William, Christopher , Faustin, Arline , Snuderl, Matija , Guzzetta, Melissa, Jarrell, Heather, Maloney, Katherine F., Reichard, Ross R., Smith, Colin , Weedn, Victor W. , Wısnıewskı, Thomas , Gould, Laura , Devinsky, Orrin , Leitner, Dominique F , Reichard, Ross, Smith, Colin , Devinsky, Orrin , Snuderl, Matija , Askenazi, Manor

Mayo Clinic

Neuropathology and Applied Neurobiology | June 23, 2021 | Volume: 48 | Issue: 1 | Pages: No page available

10.1111/nan.12746 | PMID 34164845 Get It

Abstract Aims Hippocampal findings are implicated in the pathogenesis of sudden unexplained death in childhood (SUDC), although some studies have identified similar findings in sudden explained death in childhood (SEDC) cases. We blindly reviewed hippocampal histology in SUDC and SEDC controls. Methods Hippocampal haematoxylin and eosin (H&E) slides ( n = 67; 36 SUDC, 31 controls) from clinical and forensic collaborators were evaluated by nine blinded reviewers: three board‐certified forensic pathologists, three neuropathologists and three dual‐certified neuropathologists/forensic pathologists. Results Among nine reviewers, about 50% of hippocampal sections were rated as abnormal (52.5% SUDC, 53.0% controls), with no difference by cause of death (COD) ( p = 0.16) or febrile seizure history ( p = 0.90). There was little agreement among nine reviewers on whether a slide was within normal range (Fleiss' κ = 0.014, p = 0.47). Within reviewer groups, there were no findings more frequent in SUDC compared with controls, with variability in pyramidal neuron and dentate gyrus findings. Across reviewer groups, there was concordance for bilamination and granule cell loss. Neither SUDC (51.2%) nor control (55.9%) slides were considered contributory to determining COD ( p = 0.41). Conclusions The lack of an association of hippocampal findings in SUDC and controls, as well as inconsistency of observations by multiple blinded reviewers, indicates discrepancy with previous studies and an inability to reliably identify hippocampal maldevelopment associated with sudden death (HMASD). These findings underscore a need for larger studies to standardise evaluation of hippocampal findings, identifying the range of normal variation and changes unrelated to SUDC or febrile seizures. Molecular studies may help identify novel immunohistological markers that inform on COD.
The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer
Almquist, Daniel , Savvides1, Panayiotis , Ernani, Vinicius , Savvides, P. , Almquist, Daniel R , Savvides, Panayiotis , Ernani, Vinicius

Mayo Clinic

Jornal Brasileiro de Pneumologia | June 23, 2021 | Volume: No volume available | Issue: No issue available | Pages: e20210230

10.36416/1806-3756/e20210230 | PMID 34259787 Get It

Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells
Walter, Karolin , Rodríguez-Aznar, Eva , Ferreira, Mónica S. Ventura , Frappart, Pierre‐Olivier , Dittrich, Tabea, Tiwary, Kanishka , Meessen, Sabine, Lerma, Laura , Daiß, Nora, Schulte, Lucas-Alexander , Najafova, Zeynab , Arnold, Frank , Usachov, Valentyn , Azoitei, Ninel , Erkan, Mert , Brümmendorf, Tim H. , Seufferlein, Thomas , Kleger, Alexander , Tabarés, E. , Güneş, Çagatay , Johnsen, Steven A. , Beier, Fabian , Sáinz, Bruno , Hermann, Patrick , Brümmendorf, Tim H , Kleger, Alexander , Günes, Cagatay , Johnsen, Steven A , Beier, Fabian , Sainz, Bruno , Hermann, Patrick C , Najafova, Zeynab , Lechel, André

Mayo Clinic

Cancers | June 23, 2021 | Volume: 13 | Issue: 13 | Pages: 3145

10.3390/cancers13133145 | PMID 34201898 Get It

To assess the role of telomerase activity and telomere length in pancreatic CSCs we used different CSC enrichment methods (CD133, ALDH, sphere formation) in primary patient-derived pancreatic cancer cells. We show that CSCs have higher telomerase activity and longer telomeres than bulk tumor cells. Inhibition of telomerase activity, using genetic knockdown or pharmacological inhibitor (BIBR1532), resulted in CSC marker depletion, abrogation of sphere formation in vitro and reduced tumorigenicity in vivo. Furthermore, we identify a positive feedback loop between stemness factors (NANOG, OCT3/4, SOX2, KLF4) and telomerase, which is essential for the self-renewal of CSCs. Disruption of the balance between telomerase activity and stemness factors eliminates CSCs via induction of DNA damage and apoptosis in primary patient-derived pancreatic cancer samples, opening future perspectives to avoid CSC-driven tumor relapse. In the present study, we demonstrate that telomerase regulation is critical for the “stemness” maintenance in pancreatic CSCs and examine the effects of telomerase inhibition as a potential treatment option of pancreatic cancer. This may significantly promote our understanding of PDAC tumor biology and may result in improved treatment for pancreatic cancer patients.